SCHEMBL1824032

SCHEMBL1824032

CCC(=O)Nc1ccc(COc2ccc(C(F)(F)F)c(F)c2)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.52
KDM4E B2RXH2 5/20 0.45
PKM P14618 2/20 0.45
MRGPRX4 Q96LA9 4/20 0.44
DVL1 O14640 1/20 0.44
CTSV O60911 1/20 0.42
CTSL P07711 1/20 0.42
MAOB P27338 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAOA P21397 1/20 0.40
CSF1R P07333 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
PLK1 P53350 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1822584 0.96 FFAR1 (0.55) FFAR1KDM4EPKMMRGPRX4DVL1
SCHEMBL1825703 0.92 FFAR1 (0.46) FFAR1KDM4EPKMMRGPRX4DVL1
SCHEMBL1824515 0.92 KDM4E (0.46) FFAR1KDM4EPKMMRGPRX4DVL1
SCHEMBL1826759 0.90 FFAR1 (0.46) FFAR1KDM4EPKMMRGPRX4DVL1
SCHEMBL1826068 0.89 KDM4E (0.46) FFAR1KDM4EPKMMRGPRX4DVL1
SCHEMBL1825265 0.89 MRGPRX4 (0.54) FFAR1KDM4EPKMMRGPRX4DVL1
SCHEMBL1828195 0.89 MRGPRX4 (0.46) FFAR1KDM4EPKMMRGPRX4DVL1
SCHEMBL1824518 0.88 MAOB (0.49) KDM4EPKMMRGPRX4DVL1CTSV
SCHEMBL1826571 0.87 MRGPRX4 (0.46) KDM4EPKMMRGPRX4DVL1MAOB
SCHEMBL1824746 0.87 KDM4E (0.45) FFAR1KDM4EPKMMRGPRX4DVL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US claimed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US claimed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US claimed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP claimed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US claimed
US-8461205-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2013-06-11 US disclosed
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES CHELSEA THERAPEUTICS, INC. 2012-11-08 US disclosed
US-8263658-B2 Anthranilic acid derivatives CHELSEA THERAPEUTICS, INC. (US) 2012-09-11 US disclosed
EP-2118051-B1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF CHELSEA THERAPEUTICS INC (US) 2011-05-04 EP disclosed
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES Chelsea Therapeutics, Inc 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283326-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 FFAR1 873/4885KDM4E 4207/4885PKM 3676/4885
US-20100029767-A1 ANTHRANILIC ACID DERIVATIVES ACOX3, BCL3, AOC3 FFAR1 878/4885KDM4E 4172/4885PKM 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.